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Baker, Arielle Leigh (B.A., Molecular, Cellular and Developmental Biology) 
Analysis of Tautomeric Equilibrium of the Analogue d(dinitro-tC(O))TP During 
Incorporation by the Klenow Fragment of DNA Polymerase I 
Honors Thesis directed by Professor Robert Kuchta 
 
 The studies outlined in this thesis examines the kinetic parameters of 
incorporation of the novel nucleotide analogue d(dinitro-tC(O))TP by the Klenow 
fragment of DNA polymerase I, accomplished through a series of polymerization assays. 
d(dinitro-tC(O))TP contains an additional pair of nitro groups at the top of the cyclic 
structure, expanding on the structures of previously studied synthetic nucleotides tC and 
tC(O) (Stengel et al. 2009). Nitro groups have a large electron withdrawing effect due to 
the highly electron-withdrawing oxygens, resulting in the compound being recognized 
more as T than as C when compared to the parent tC and tC(O). KF incorporates d(dinitro-
tC(O))TP as efficiently as dTTP opposite a templating adenosine base, and about twice as 
efficiently as dCTP opposite guanosine. 
My studies on d(dinitro-tC(O))TP support the existing hypothesis that selection for 
the correct nucleotide based on size is only true for analogues closely related to the 
canonical bases. KF appears to use both the size and hydrogen bonding patterns of 
incoming nucleotides to distinguish their correctness. The ability of d(dinitro-tC(O))TP to 
hydrogen bond in a manner similar to its parent compound, cytosine, allows the 
compound to be incorporated by KF while the bulky cyclic addition is not detrimental 
enough to sterically inhibit incorporation. The efficient incorporation opposite both A and 
G is consistent with it existing in roughly equal amounts of the two tautomers, amino (C-
like) and imino (T-like). d(dinitro-tC(O))TP is an exciting compound because it retains 
traditional hydrogen bonding properties, thereby maintaining the identified prerequisite 
for selection of the correct incoming nucleotide, but expands upon the traditional cytosine 
structure by expanding into the major groove. Though not therapeutically viable, 
d(dinitro-tC(O))TP offers interesting insight into the effect of electron-withdrawing groups 
on tautomeric equilibrium when added to a nucleotide analogue. 
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I. Introduction 
DNA REPLICATION 
Cellular replication, proliferation and survival are contingent upon the process of 
DNA replication. In many domains of life, there are common features to the replication 
process, not only in its mechanisms but also in its machinery. This machinery includes 
DNA helicases, which topologically prepare the DNA helix by unraveling it; single-
stranded DNA binding (SSB) proteins, which help to prevent reannealing of the DNA 
strands after unwinding by helicases as well as prevent destruction of the ssDNA by 
nucleases; primases, which synthesize a primer on the DNA template to which 
polymerases can adhere and begin elongation; topoisomerases, which relieve supercoiling 
stress in the DNA strand generated by helicase unwinding; and DNA polymerases, which 
synthesize daughter DNAs complementary to each single-stranded parent DNA in a 
semi-conservative fashion. 
Replication is an intricate process. It requires the perfect orchestration of a 
number of enzymes, and involves precisely copying genomes containing millions to 
billions of nucleotides. Despite these factors, replication of the genome is incredibly 
accurate; rarely do DNA polymerases incorporate the incorrect nucleotide. For A family 
polymerases, the frequency of error is approximately 10-3 to 10-6 errors per nucleotide 
inserted (Kunkel and Bebenek 1988). Many DNA polymerases also have exonuclease 
active sites that provide proofreading functions, which will repair many errors by 
excising incorrectly incorporated nucleotides, thus decreasing the misincorporation rate 
even further. Finally, repair enzymes that follow the replication machinery carry out a 
final examination of the replicated DNA, decreasing the frequency of errors to 
approximately 10-9 errors per nucleotide inserted (Roberts and Kunkel 1996). It is 
important to note that while erroneous replication can have deleterious consequences, 
evolution is founded in erroneous replication. 
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DNA POLYMERASE 
There are several families of polymerases found in a variety of organisms, 
including A, B, C, X, Y and RT. DNA polymerases are classified according to a variety 
of structural homologies, both in sequence and in conformation. The studies I conducted 
utilized the Klenow fragment of DNA Polymerase I (Pol I) from Escherichia coli, an A 
family polymerase. Pol I was the first identified polymerase (Kornberg 1960). In general, 
A family polymerases replicate DNA with high fidelity, working with other accessory 
proteins and subunits to achieve a finished product. Pol I also functions in nucleotide 
excision repair (Rothwell and Waksman 2005). 
DNA polymerases have similar structures across the different families. One 
distinctive feature of polymerases is their hand-like shape (Figure 1.1). 
The hand contains 
subdomains that resemble a 
palm, fingers and a thumb 
(Wang et al. 1997). The palm, 
similar to a human hand, is 
situated between the fingers 
and the thumb subdomains; this 
contains the active site where 
dNTPs enter the complex to be 
catalytically incorporated 
(Figure 1.1). The palm domains 
of different polymerase 
families are largely 
superimposable (Li and 
Waksman 2001), highlighting the evolutionary adaptation of the enzyme. The fingers 
work to recognize incoming nucleotides, and help orient them to bind, while the thumb 
helps to bind the DNA substrate (Figure 1.1) (Klenow and Henningsen 1970; Wang et al. 
1997). 
The Klenow fragment of DNA Polymerase I is an important catalytic protein. 
First discovered in 1970, it was the first solved polymerase crystal structure (Ollis et al. 
Figure 1.1: Model for a replicative DNA polymerase. The 
differing domains are indicated, as well as the parent DNA 
strand (brown), the daughter DNA strand (yellow) and a dNTP 
(black) (DePamphilis 2006). 
	   9	  
1985). KF is formed from Pol I by removing its 5’—3’ exonuclease domain. The cleaved 
enzyme retains 5’—3’ polymerase activity and its 3’—5’ exonuclease domain (Klenow 
and Overgaard-Hansen 1970; Zhao et al. 2013; Zhao and Guan 2010). The 3’—5’ 
exonuclease domain can be knocked out, which is the case for the KF utilized in this 
study. 
Because of the importance of ensuring accurate genomic replication, many studies 
focus on the importance of polymerase fidelity, examining the various mechanisms by 
which polymerases distinguish between correct and incorrect nucleotides (Prindle et al. 
2013; Donigan et al. 2014). Homologies in polymerase structure and function raise the 
question of why certain types of polymerases are significantly more efficient or accurate 
than other polymerases (Yao and Müller 2011; Nemec et al. 2014). 
 
NUCLEOTIDE DISCRIMINATION BY DNA POLYMERASES 
Nucleotides are compounds naturally created within cells that are utilized in a 
variety of ways, ranging from traditional 
RNA and DNA synthesis to metabolism, 
signaling within the cell, and regulation of 
enzyme activity (Jordheim et al. 2013). 
There are four canonical bases found in 
DNA: guanine, cytosine, adenine and 
thymine. Specific nucleobases express 
pairing preferences based on the size and 
stereochemistry of their nucleotide 
partners; cytosine and guanine are pairs, 
and adenine and thymine are pairs (Figure 
1.2). Francis Crick and James Watson 
largely pioneered this research, finding 
that alternate tautomeric forms of natural 
nucleotides could account for mutations in DNA (1953). They used a model to determine 
that cytosine and adenine had the ability to mutagenically pair with each other using 
amino and imino tautomeric forms, and that thymine and guanine could mutagenically 
Figure 1.2: The chemical composition of DNA. 
This model shows the four bases adenine, thymine, 
cytosine and guanine, and the backbone. The 
backbone is composed of phosphorylated 
deoxyribose sugars (Klotsa et al. 2005). 
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pair with each other using keto and enol tautomeric forms; because adenine and guanine 
are purines, and thymine and cytosine are pyrimidines, these tautomeric forms can exist 
without causing a large structural disturbance (Morgan 1993; Urban et al. 2010; Hirao et 
al. 2012). 
A foundational property of the discovery of DNA structure was the identification 
of the hydrogen bonding patterns between nucleobases. These distinctive patterns are 
thought to be a basis upon which polymerases discriminate incoming nucleotides (Moore 
et al. 2004; Ramirez-Aguilar et al. 2005; Wolfle and Washington 2005; Choi et al. 2009). 
It appears that A family polymerases use a mélange of positive and negative selectivity in 
nucleotide discrimination. Pol I, which is a high-fidelity polymerase, does not appear to 
utilize hydrogen bond pairing to achieve efficient nucleotide incorporation (Chiaramonte 
et al. 2003; Trostler et al. 2009); these mechanisms will be discussed in detail later. 
Nucleoside and nucleotide analogues are chemically altered agents that are made 
to simulate the actions of their physiological counterparts, but with key differences. 
Perhaps the most famous analogue alteration development came from researchers 
Gertrude Elion and George Hitchings, who developed, among other drugs, 
acycloguanosine for the treatment of herpes; their discoveries led to development of 
AZT, for the treatment of AIDS. Since their remarkable discovery, scientists continue to 
toy with these useful compounds, producing a variety of novel structures. These 
alterations can be made on different structural components of the nucleotide. These 
developments have been built on previous knowledge on how correct nucleotides are 
selected and incorporated by polymerases. Not only are analogues being tested clinically, 
but a large number are used clinically as chemotherapeutics for both cancer and viral 
infection. 
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The mechanism by which Pol I 
may in some cases choose its substrate 
appears to be through evaluation of the 
shape of the incoming nucleotide (Kool 
2002). This mechanism has been explored 
using analogues of traditional nucleotides, 
with altered or removed hydrogen bonding 
capabilities. In addition to shape and 
hydrogen bond features, investigations 
have also included consideration of the 
hydrophobicity and polarity of nucleotides 
being incorporated. Studies by Urban et al. 
conclude that primer elongation rate by 
Pol I decreases significantly when the 
incoming dNTP is unable to hydrogen 
bond to its templating base in a manner 
consistent with canonical Watson-Crick 
base-pairing (2009; 2010). The acceptors 
of hydrogen bonds contained within the 
minor groove appear to be of particular 
importance to nucleotide incorporation 
(Seeman et al. 1976; Hendrickson et al. 2004). 
Studies thus indicate that the ability of nucleobases to form canonical hydrogen-
bonding interactions during incorporation is of paramount importance in determining the 
efficiency of A family polymerases. Chiaramonte et al., however, showed that Klenow 
fragment has the ability to incorporate nucleotides whose shapes differ significantly from 
those of canonical nucleotides (2003). The analogues studied, which are shown in Figure 
1.3, have novel and distinct shapes, leading to alternative hydrogen bonding patterns. 
These studies help to conclude that polymerases of the A family do not 
discriminate between nucleobases based solely on shape or hydrogen bond patterns, 
allowing them to efficiently incorporate a variety of compounds. Knowing what features 
Figure 1.3: Sample nucleobase analogues that 
lack shape and hydrogen bonding 
complementarity yet are incorporated very 
efficiently by A family polymerases 
(Chiaramonte et al. 2003). 
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A family polymerases do not use to discriminate, termed negative selection, a study by 
Trostler et al. set out to determine what aspects of the nucleotide is used for 
discrimination, termed positive selection. Using Pol I of Bacillus stearothermophilus, the 
group studied a number of purine analogue triphosphates (Figure 1.4) in which the N-1, 
N-3 and N6 of the purine ring were systematically replaced with carbons. 
 This results in a decreased efficiency of correct incorporation opposite T, 
particularly with substitution of the nitrogen for a carbon in the heterocycle in the 1 or 3 
position 
(2009). This 
indicates 
that Pol I 
does not 
merely 
evaluate the 
shape or the 
hydrogen 
bonding 
ability of a 
given 
nucleotide; 
the 
composition 
of the 
heterocycle 
plays a key role in ensuring correct incorporation, steering the polymerase away from 
mutagenic base pairing. Thusly, one can see that it is of paramount importance to 
consider not only the addition of groups to the canonical compounds, but also the 
composition of the cyclic portion of the structure itself.  
 
 
 
Figure 1.4: Purine analogues utilized to probe the roles of specific chemical features 
of the natural purine nucleobases (Trostler et al. 2009). 
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THERAPEUTICS 
The important role of nucleotides in so many cellular processes has prompted 
investigation into their clinical applications, and analogues are an excellent avenue for 
current and future therapeutics. Structural alterations allow researchers to manipulate the 
nuances of replication and nucleotide metabolism, thereby affecting a plethora of 
intracellular activities (Jordheim et al. 2013). Notably, analogues can inhibit DNA and 
RNA synthesis, thus halting cellular division and/or viral replication (De Clerq and Neyts 
2004). Nucleotide and nucleoside analogues, then, represent powerful treatments for 
cancer tumor suppression and anti-viral therapy (Pockros 2013), as well as 
unconventional approaches to mechanisms involved in polymerase and 
phosphodiesterase inhibition, epigenetic modulation, immunosuppression, 
neuroprotection and cardioprotection (Moyle 2000; Squires 2001). 
In order for nucleoside analogues to be functional, they must undergo 
phosphorylation within the cell by nucleoside kinases, (d)NMP kinases and NDP kinase; 
triphosphorylation is necessary for nucleotides to become active in the body. Some 
nucleotide analogues already have this phosphorylation completed, and are thus already 
chemically active, but are unable to enter the cell because of the inability for charged 
phosphate groups to penetrate the hydrophobic cell membrane (Pockros 2013; Squires 
2001). Thus, phosphorylation must be completed once inside the cell, which is a current 
challenge to clinical application. 
 
THERAPEUTIC MECHANISMS OF ACTION 
Nucleotide and nucleoside analogues often behave as anti-metabolites in the 
process of nucleic acid metabolism. They can utilize the exact metabolic pathways that 
are used by natural nucleosides and nucleotides (Jordheim et al. 2013). Classical 
nucleotides are hydrophilic in nature, and are derived from two pathways: the de novo 
pathway and the salvage pathway. The de novo pathway converts various small 
molecules into nucleoside triphosphates; this pathway, then, is essential in replication of 
cells. The salvage pathway, on the other hand, recycles leftover nucleosides from DNA 
and RNA catabolism (Kufe et al. 1984). Exogenous nucleotides use kinases of the 
salvage pathway. These analogues are ingested by cells through compound-specific 
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membrane transport carriers or via passive diffusion across the plasma membrane 
(Minuesa et al. 2011; Cano-Soldado and Pastor-Anglada 2012). Ongoing research 
indicates that some antiviral analogues can be taken up by organic anion and cation 
transporters, in addition to peptide transporters (Roizman et al. 2001), but this data is 
presently inconclusive. 
 Once ingested, the analogues undergo a series of phosphorylation events, 
allowing di- and tri-phosphorylated analogues to collect in the target cells. Without these 
phosphorylation steps, the drugs remain inactive (Jordheim et al. 2013). The active 
analogues are then readily available for incorporation into DNA and RNA strands being 
synthesized, or for inhibition of enzymes other than polymerases, or oftentimes for both. 
Many analogues, due to the structural and chemical changes they possess, cause 
elongation to halt, as the polymerase enzyme cannot extend the strand past such a 
compound (Pockros 2013). Typically in replication of the viral genome, incorporation of 
analogues causes the cell to recognize the strand as severely mutated, causing replication 
termination of the viral DNA or RNA, called error catastrophe (De Clerq and Neyts 
2004; Leyssen et al. 2008;). Researchers postulate that analogues results in a chain-
termination event that prevents progression of the cell cycle S phase (Ewald et al. 2008), 
but further research in this area is needed in order to draw more decisive conclusions. 
It is important to understand the structural and mechanistic basis for nucleotide 
and nucleoside analogues in order to develop new compounds. Such considerations have 
fostered the creation of agents that interact more efficiently with membrane transporters, 
or that are less liable to degradation (Jordheim et al. 2013). New compounds can be 
developed with enhanced properties that increase the efficiency and rate of success of 
nucleotide and nucleoside analogues as therapeutics (Pockros 2013). Research in the 
nucleotide and nucleoside analogue field has seen the development of many new 
nucleoside drugs, several of which are presently in early-phase clinical trials, and a 
significant number that have become regularly prescribed drugs (Jordheim et al. 2013). I 
will briefly review the history and present state of such therapeutics, to set the stage for 
the investigation of d(dinitro-tC(O))TP.  Nucleoside and nucleotide analogues fall into two 
primary therapeutic categories: anticancer compounds and antiviral compounds. 
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II. Anticancer Nucleotide and Nucleoside Analogues 
 
The first anticancer nucleoside analogue that targeted DNA polymerases was 
cytarabine (Figure 2.1) for acute myeloid leukemia; approval of this compound by the US 
Food and Drug Administration (FDA) in 1969 initiated a cascade of compound 
development for anticancer therapeutics (USA National Institutes of Health 2011). 
In terms of anticancer nucleoside analogues, as of 2007, 
nine are currently approved and on the market: cytarabine, 
fludarabine, cladribine, gemcitabine, clofarabine, nelarabine, 
capecitabine, floxuridine, and deoxycoformycin (Nekhai et al. 
2007). These drugs treat specific types of cancer, and are 
largely derivatives of deoxycytidine, deoxyadenosine or 
deoxyguanosine (Van Rompay et al. 2003; Galmarini et al. 
2010; Senanayake et al. 2011). Two additional compounds, 
azacitidine (Kaminskas et al. 2005) and decitabine (Stewart et 
al. 2009; Jordheim et al. 2013) are known as demethylating 
agents and act through a different mechanism to prevent 
proliferation in cancer cells. 
Presently, many consider existing anticancer agents to not be impactful enough to 
merit continued clinical treatment. Cytarabine, the most powerful clinically used 
compound, provides cures of acute myeloid leukemia in fewer than 30% of all adult 
patients (Kantarijian et al. 2012). A couple of other cytotoxic nucleoside analogues have 
been developed (Jordheim et al. 2013), but do not impact the patient long-term, simply 
prolonging survival, but not ultimately curing the cancer. 
A few of the newly developed nucleoside analogues have the same cytotoxic 
mechanisms as those of older nucleoside analogues. One such compound is 1-(2-C-
cyanodeoxybeta-D-arabino-pentofuranosyl) cytosine (Figure 4), also referred to as 
CNDAC (Jordheim et al. 2013), from which an orally administered drug has been 
created: sapacitabine (Figure 2.2) (Chaio et al 2013).  
Figure 2.1: Chemical 
structure of 
cytarabine (USA 
National Institutes of 
Health 2011). 
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CNDAC is a 
cytarabine analogue that 
functions by cleaving the 
DNA strand through 
nucleophilic attack of the 
cyano groups. Human 
cancer xenografts 
responded well in vivo to 
both CNDAC and sapacitabine. This has resulted in the initiation of sapacitabine’s 
clinical testing, as well as in combination with other anticancer agents, and appears to 
have a beneficial effect in patients being treated for chronic lymphocytic leukemia, acute 
myeloid leukemia, as well as some small tumors, largely by inhibiting the polymerases 
that copy genetic information. By disallowing these processes to occur, sapacitabine 
prevents the growth of tumors (Kantarjian et al. 2012). 
 Another realm of anticancer analogue research is focused on inhibiting RNA 
synthesis (Krett et al. 2004). Two such compounds utilized in this research are 8-chloro 
adenosine and 8-amino-adenosine. 8-Chloro-adenosine decreases RNA synthesis while 8-
amino-adenosine decreases both RNA and DNA synthesis (Gandhi et al. 2001). This 
results in a decrease in the production of a variety of proteins. The cytotoxic effects of 8-
chloro-adenosine are manifested in decreased expression of MET. MET is the receptor 
for hepatocyte growth factor in myeloma cells (Stellrecht et al. 2007). 8-Chloro-
adenosine is also implicated in decreased cyclin-E expression in breast cancer cells. Due 
to these properties, this compound is presently being clinically investigated in a Phase I 
clinical trial (Stellrecht et al. 2010; Jordheim et al. 2013). 
 And yet, these compounds display inconsistency in terms of impact, largely due to 
patient variability. For example, cytarabine, as well as fludarabine, are functional in a few 
hematological malignancies, but not in solid tumors. This inconsistency may rise from a 
matter of patient variability or a mechanism of action. The compounds are specific for 
reasons not yet understood. The effects of gemcitabine (Figure 2.3) are presently the most 
consistently predictable in the field of anticancer nucleoside analogues; it displays 
activity in both hematological malignancies and several solid tumors (Song et al. 2013). 
Figure 2.2: Chemical structures of sapacitabine (left) and CNDAC 
(right) (Chaio et al. 2013). 
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These studies have shaped the direction of current cancer therapeutics research—research 
has evolved from the notion of an overlying “cancer treatment”, due to tumor specificity; 
rather, current efforts aim to treat each tumor type as a separate disease. 
 4’-Thioaracytidine is a nucleoside in which the 
sugar has been modified, and demonstrates antitumor 
activity in several tumor subtypes. 4’-thioaracytidine 
exhibits a unique ability to retain a tri-phosphorylated 
state, unlike cytarabine and fludarabine. A tri-
phosphorylated state is more difficult to degrade 
intracellularly, thus making it a more stable compound. 
4’-Thioaracytidine is currently being evaluated in Phase I 
clinical trials (Someya et al. 2006). 
Many anticancer compounds can also target 
viruses, the most prominent of which is cytarabine 
(Figure 2.1). Cytarabine can target herpesvirus infection (Renis 1973; Hryniuk et al. 
1972). The compounds toxacitabine and 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-
guanine, both of which are anticancer compounds, display promising attributes in their 
pre-clinical trials (Jordheim et al. 2013). 
Troxacitabine (Figure 2.4) is a synthetic nucleotide analogue (Galmarini et al. 
2001) that, in pre-clinical trials, appeared to behave as an antitumor agent (Grove et al. 
1995; Kadhim et al. 1997; Parker 2013). 
It has a nontraditional stereochemical 
configuration, and is the first of its kind to be 
developed clinically. Being a nucleoside analogue, 
troxacitabine requires phosphorylation in vitro by 
cellular kinases, after which its incorporation into the 
DNA strand causes inhibition of the polymerase.  
This compound does not have inhibitory effects on 
ribonucleotide reductase nor mitochondrial DNA 
synthesis; in the case of gemcitabine, the inhibition of 
ribonucleotide reductase may enhance its efficacy. 
Figure 2.3: Chemical 
structure of gemcitabine 
(Song et al. 2013). 
Figure 2.4: Chemical structure of 
troxacitabine (Galmarini et al. 
2001). 
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Trozacitabine is hence in phase II testing due to its breadth: it is cytotoxic against both 
leukemic and epithelial malignancies, and may have effects on acute leukemia (Giles et 
al. 1999; Jordheim et al. 2013). 
The compound 9-beta-arabinofuranosylguanine, also referred to as ara-G (Figure 
2.5), is a distinctive anticancer nucleoside analogue (Galmarini et al. 2001) that exhibits 
resistance to cleavage by purine nucleoside phosphorylase (PNP) (Mahmoudian et al. 
1999).  
Pre-clinical trials revealed that ara-G was toxic to 
T-lymphocytes, and therefore represented a powerful 
antitumor candidate, but development of this compound 
was halted due to problems with insolubility in water 
(Aguayo et al. 1999). This led researchers to the discovery 
of the compound 2-amino-9-beta-D-arabinosyl-6-
methoxy-9H-guanine, also referred to as GW506U78, 
which is a derivative of ara-G, but with improved 
solubility, allowing the compound the access the cell 
(Aguayo et al. 1999). After accessing the cell, GW506U78 
can then be converted to ara-G via plasma adenosine 
deaminase (Kurtzberg et al. 1999; Jordheim et al. 2013). 
 Troxacitabine and GW506U78 are excellent examples of the progression of 
anticancer nucleoside and nucleotides analogue research. Developmental research on 
troxacitabine has helped researchers understand the selectivity of its stereochemistry in 
regards to specific types of DNA. This enables researchers to develop selective drug 
targets. The logical development of GW506U78 from ara-G demonstrates the ability of 
researchers to examine analogues structurally, and make appropriate changes based on 
specific properties of that compound. This is the direction of current nucleoside and 
nucleotide analogue research— trial and error, slowly molding the ideal compound for 
particular cancer or viral infection types. This will yield new agents with enhanced 
solubility and bioavailability, as well as the ability to overcome resistance mechanisms 
(Jordheim et al. 2013). 
Figure 2.5: Chemical structure 
of ara-G (Mahmoudian et al. 
1999). 
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 Research on anticancer nucleoside and nucleotide analogues has brought about 
the development of many successful candidates for therapeutics. The breakthroughs with 
cytarabine and other analogues brought about a profound interest in nucleoside and 
nucleotide analogues for anticancer therapeutics. Studies on the chemical structure of 
novel compounds, however, have brought about candidates for specificity and retention. 
Thusly, there is significant effort being made to improve their utility. These novel 
analogues exhibit the potential to transform the position of nucleoside and nucleotide 
analogues in cancer therapy. 
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III. Antiviral Nucleotide and Nucleoside Analogues 
 
 Antiviral nucleoside analogues emerged in 1969, the first of which was 
edoxudine. Since the development of edoxudine, 24 additional antiviral nucleoside and 
nucleotide analogues have been created and approved by the FDA. Antiviral analogues 
can target several viruses, including HIV, HBV, CMV and HSV infections (De Clercq 
and Holy 2005). HIV, HBV and HCV infections are life threatening and chronic, and 
represent the largest class of antiviral research; these infections affect about 600 million 
people throughout the world (Hurwitz and Schinazi 2013). Another classification is acute 
infections: independent viruses that cycle through the population with minor impact for 
the majority of people, but dangerous to some individuals, such as pregnant and feeding 
women, or the elderly (De Clerq and Holy 2005). The final classification of viral 
infections is those that are common, such as a cold (caused by rhinoviruses), but do pose 
an economic impact in the form of sick employees. 
 The ability of nucleoside and nucleotide analogues to treat a variety of viral 
diseases is both a benefit and a potential roadblock It is beneficial because it allows one 
simple mechanism to be applied across the board to many diseases without extensive 
time used and research to be conducted. It can be problematic, however, because each 
virus is specific, variable and irregular, making it difficult to predict the outcome of 
clinical application of a given antiviral agent (Jordheim et al. 2013). There are four main 
antiviral targets: HBV, HCV nucleosides, HIV nucleosides, 
and herpes. 
Anti-HCV nucleoside analogues largely revolve 
around the compound 2’-deoxy-2’fluorocytidine (FdC) 
(Figure 3.1), and chemically altered derivatives (Stuyver et 
al. 2004). One such derivative is valopicitabine, which was 
the first clinically used anti-HCV nucleoside analogue. 
Valopicitabine can function by itself, but is often combined 
with pegylated interferon or ribavirin, to decrease chance of 
resistance. The success of this compound prompted the 
Figure 3.1: Chemical structure of 
FdC (Stuyver et al. 2004). 
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development of more anti-HCV compounds, notably mericitabine. Mericitabine is 
another FdC derivative that is currently in Phase II clinical trials, and is presently on the 
forefront of anti-HCV nucleoside development (Le Pogam et al. 2010; Wedemeyer et al. 
2013). 
 Anti-HIV nucleosides are dideoxyribose derivatives. One particularly potent 
derivative is apricitabine, which has elevated genetic resistance, making it an attractive 
agent. Apricitabine functions best against HIV-1 strains and HIV strains with mutations 
in reverse transcriptase. In 2005, tested over a 48-week treatment period, apricitabine was 
highly effective and did not show signs of resistance (Bethall et al. 2005). Despite 
anticipation of its arrival on the market in 2010, however, apricitabine was suddenly 
withdrawn, seemingly due to legal and commercial complications. One year later, it was 
reinstituted as an anti-HIV candidate, and is currently in Phase III clinical trials (Cahn 
and Wainberg 2010). Apricitabine represents the progression of anti-HIV analogues, as 
well as that which needs to be addressed in future compounds: apricitabine is a worthy 
candidate due to its resistance to mutation; this effect ought to be taken into consideration 
upon further development of more anti-HIV nucleosides. Studies since the development 
of apricitabine have led to the generation of the compound festinavir. Festinavir, which is 
a derivative of an early anti-HIV nucleoside analogue names stavudine but with an 
additional 4’ position ethynyl group on the ribose ring, has been found have reduced 
toxicity in patients, as well as increased potencies. Festinavir, then, expresses properties 
better than its forefathers, and is presently being 
evaluated in Phase II clinical trials. It has a prolonged 
antiviral effect, and is an attractive model for 
development of differing antiviral drug resistance 
profiles. 
 Anti-herpes nucleosides are acyclic sugars. The 
most famous anti-herpes nucleoside on the market is 
acyclovir, from which stemmed several other compounds: 
ganciclovir, penciclovir, and most recently, 
cyclopropavir. Cyclopropavir (Figure 3.2) is a derivative 
of the traditional nucleoside guanosine, but with a 
Figure 3.2: Chemical structure 
of cyclopropavir (Chou et al. 
2012). 
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methylenecyclopropane group as a side chain (Chou et al. 2012). Cyclopropavir is 
interesting because it combats multiple strains of herpesvirus, including human 
herpesviruses 6A, 6B and 8, and human cytomegalovirus (Price and Prichard 2011). It 
exhibits many unique properties not present in currently approved anti-herpes agents, 
including the ability to inhibit replication of human cytomegalovirus, and the ability to 
remain continuously active against ganciclovir-resistant strains (Chou and Bowlin 2011). 
 Antiviral nucleosides and nucleotides have seen an influx of development over 
the past ten years, making them attractive subjects for future studies. Future research, 
however, needs to focus on ensuring the analogues’ incorporation into the viral genome, 
and not the genomic and mitochondrial DNA of the host cells. In addition, it is important 
that a variety of compounds continue to be developed, to stave off resistance to particular 
compounds by viruses being treated solely by a few compounds (Jordheim et al. 2013). 
Effective treatment will most likely require the use of many compounds, for which 
research ought to be continued. 
 The success and failures of current therapeutics, as well as the number of studies 
elucidating DNA polymerase mechanisms, have helped develop a greater understanding 
of the way in which polymerases accurately and successfully incorporate a given 
nucleotide. This research has lead to the amelioration of current nucleotide analogues, 
and still leave quite a bit of room for development of further systems.  
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IV. tC, tC(O), and dinitro-tC(O) 
tC AND tC(O) 
A study conducted in 2009 investigated of the compound 1,3-diaza-2-oxo-
phenothiazine (tC) and its oxo-homolog, 1,3-diaza-2-oxo-phenoxazine (tC(O)) (Figure 
4.1) (Stengel et al.). 
These compounds are 
unique cytosine 
analogues with 
fluorescent properties. 
Unlike traditional 
cytosine, tC contains 
substantial extra mass 
in the major groove, but 
remains similar to 
cytosine in its hydrogen 
bonding abilities (Stengel et al. 2009). Extensive studies characterizing these compounds 
in relation to all four natural nucleobases using the KF of DNA Pol I helped elucidate 
their incorporation properties. 
Stengel et al. discovered many unique characteristics of these compounds. KF 
inserts dtCTP and dtC(O)TP efficiently opposite both G and A. KF inserts both analogues 
opposite G with the same efficiency (defined by Vmax/KM) with which dCTP is inserted. 
KF incorporated the analogues approximately 4- to 11-fold less efficiently opposite 
template A than incorporation of dTTP. The KF is able to distinguish the structure of the 
template, thereby not generating dtC(O)TP-pyrimidine mismatches. KF polymerizes 
dtCTP and dtC(O)TP 200- and 1000-fold less effectively opposite T, respectively, than it 
does dATP (Stengel et al. 2009). 
Many N4-substituted cytosine analogues prefer to exist in the imino tautomer 
(Harris et al. 2003). The analogues tC and tC(O), however, have an unclear tautomeric 
equilibrium- and one cannot determine the tautomeric equilibrium base solely on 
structure. The compounds likely base pair with G in the amino tautomer, and in the imino 
tautomer they base pair with A (Figure 4.1). Polymerization favored the amino tautomer 
Figure 4.1: Hydrogen bonding of the amino and imino tautomers of tC 
with G and A, respectively (X = S for tC; X = O for tC(O)) (Stengel et al. 
2009). 
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10:1 because the amino tautomer is 10-fold more stable; this helps to explain why 
multiple polymerases are able to insert the compound more efficiently opposite G than A 
(Table 4.1).  
 
The studies by Stengel et al. investigated incorporation of dtCTP and dtC(O)TP by both 
KF and pol α, as well 
as some studies using 
BF pol and HSV pol, 
and found that despite 
differing substrate 
specificities, they 
polymerize the 
analogues with 
strikingly similar 
efficiency. The 
formation of base pairs 
occurs nearly identically regardless of placement of the analogue in the primer or the 
template strand, thereby showing that the imino tautomer of tC(O) is the main proponent 
of mutagenic pairing opposite A. Calculation of Vmax/KM found that the tautomeric 
equilibrium of tC and tC(O) is relatively the same; this demonstrates that the tautomeric 
equilibrium plays a significant role in defining incorporation ability (Stengel et al. 2009).  
 
d(dinitro-tC(O))TP: A NOVEL NUCLEOTIDE ANALOGUE 
The nucleotide analogue d(dinitro-tC(O))TP (Figure 4.2) was synthesized in 
December 2011 by Brittney Rodgers and 
Byron Purse of the Purse Laboratory at the 
University of San Diego. 
Due to the structural similarities of 
dinitro-tC(O) to tC and tC(O) , I founded my 
assays on the studies of these compounds. 
Whereas tC and tC(O) are derived from 
dNTP DNA Vmax 
KM 
[µM] 
Vmax/KM Discrimination 
dTTP DNAA 4.1 0.6 6.5 1 
dtCTP DNAA 1.6 2.7 0.6 11 
dtC(O)TP DNAA 2.2 2.4 0.9 7 
dCTP DNAG 3.63 0.23 15.8 1 
dtCTP DNAG 4.5 0.18 25 0.6 
dtC(O)TP DNAG 3.4 0.13 26.2 0.6 
Table 4. 1: Kinetic parameters for incorporation of dtCTP and dtC(O)TP 
analogues into DNAA and DNAG by KF (Stengel et al. 2009). 
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Figure 4. 2: Chemical structure of d(dinitro-
tC(O))TP (amino tautomer). 
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cytosine via an expansion of the carbon ring at the N4 and C5 positions (Stengel et al. 
2009), d(dinitro-tC(O))TP has an additional two nitro groups at the top of the tricyclic 
portion of the structure. I examined the incorporation of a triphosphorylated dinitro-tC(O) 
opposite natural bases, characterizing the structural and electronic properties of the 
compound to understand its incorporation preferences using the Klenow Fragment of 
DNA polymerase I. Nitro groups are extremely electron withdrawing. My studies aim to 
address how the two nitro groups affected the tautomeric equilibrium between imino and 
amino forms. 
 
ASSAY METHODOLOGY 
All reagents were of highest quality commercially available. Unlabeled dNTPs 
were purchased from Invitrogen. d(dinitro-tC(O))TP was synthesized in the Purse 
Laboratory at University of San Diego. E. coli DNA Polymerase I Klenow fragment 
(exo-) was purchased from New England Biolabs.  
 
5’-labeling of primer strands 
DNA primers were 5’-32P-labeled using T4 polynucleotide kinase (purchased 
from New England 
Biolabs) and [ ! -
32P]ATP. The labeled 
primer was annealed to 
the appropriate 
template strands. The 
sequences of the used 
primer-templates are given in Chart 1. 
 
Polymerization assays 
All kinetic data were determined under steady-state conditions. 
The reactions with KF contained 2 µM 5’-32P-primer-template, 5 mM MgCl2, 50 
mM Tris-HCl pH 7.5, and varying concentrations of natural or analogue dNTPs in a total 
volume of 10 µl. Reactions that served to derive kinetic parameters contained 0.5 nM KF 
Chart 1: Sequences of Primer-Templates. The letter after "DNA" 
designates the template base being replicated. 
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(-exo). Polymerization was initiated by mixing equal volumes of reaction mixture and 
enzyme followed by incubation at 37 ºC. The reactions were stopped by addition of two 
volumes gel loading buffer (90% formamide with 50 mM EDTA) after 1—10 minutes. 
Extension products were separated by denaturing gel electrophoresis (20% 
polyacrylamide, 8 M urea) and analyzed by phosphor imaging (Typhoon scanner, 
Molecular Dynamics). The parameters KM and Vmax were obtained by nonlinear curve 
fitting. 
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V. Results 
KF inserts d(dinitro-tC(O))TP efficiently opposite G and A 
 The single nucleotide insertion assays evaluated the incorporation of d(dinitro-
tC(O))TP opposite guanosine and adenosine; G and A were positioned on synthetic 
oligonucleotides (Chart 1); these assays allowed for the determination of the KM and 
Vmax. 
Preliminary experiments indicated poor to nonexistent incorporation of d(dinitro-
tC(O))TP opposite T and C. 
Knowing that d(dinitro-tC(O))TP is derived from the canonical pyrimidine dCTP, I 
wanted to investigate its ability to be incorporated across from a templating guanosine. 
Figure 5.1 shows the result. 
 
 
 
 Knowing the ambivalence with which dtCTP and dtC(O)TP were incorporated 
opposite both a templating guanosine and adenosine, I investigated the incorporation of 
d(dinitro-tC(O))TP across from a templating adenosine. Figure 5.2 shows the result. 
Figure 5.1: Primer elongation by KF after incorporation of d(dinitro-tC(O))TP. The 
primer/template sequence is shown above the figure. Assay contained: 2 µM 
DNAG/standard primer; 2, 5, 10, 20, 40 and 500 µM dCTP. The enzyme concentration 
was 0.5 nM KF. The time points recorded were 2.5 and 10 minutes. 
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Graph 5.1 visually depicts the Michaelis-Menten kinetics with which d(dinitro-tC(O))TP 
is incorporated opposite a templating adenosine. 
 
	  
Graph 5.1: Michaelis-Menten parameters for incorporation of d(dinitro-tC(O))TP opposite template 
adenosine. 
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Figure 5.2: Primer elongation by KF after incorporation of d(dinitro-tC(O))TP. The 
primer/template sequence is shown above the figure. Assay contained: 2 µM 
DNAA/standard primer; 2, 5, 10, 20, 40 and 500 µM d(dinitro-tC(O))TP; 0.5, 0.75, 1, 2, 
4 and 6 µM dTTP. The enzyme concentration was 0.5 nM KF. The time points 
recorded were 2.5 and 10 minutes. 
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Graph 5.2 visually depicts the Michaelis-Menten kinetics with which dTTP, the correct 
nucleotide, is incorporated opposite a templating adenosine. 
 
	  
Graph 5.2: Michaelis-Menten parameters for incorporation of dTTP opposite template adenosine. 	  
Table 5.1 shows the quantitative data of how the rates of incorporation compared. 
 
dNTP DNA Vmax KM [µM] Vmax/KM Discrimination 
dTTP DNAA 2.47 0.32 7.70 1 
d(dinitro-tC(O))TP DNAA 2.38 0.25 9.48 1.23 
dCTP DNAG 0.69 0.19 3.59 1 
d(dinitro-tC(O))TP DNAG 2.93 0.38 7.70 2.15 
 
KF polymerizes d(dinitro-tC(O))TP opposite A with approximately the same 
efficiency, Vmax/KM, with which it inserts the correct nucleotide, dTTP. KF polymerizes 
d(dinitro-tC(O))TP opposite G with approximately 2-fold more efficiency than it does the 
correct nucleotide, dCTP (Table 5.1). 
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Table 5. 1: Kinetic parameters for incorporation of d(dinitro-tC(O))TP analogues and their correct 
counterparts into DNAN by KF. 
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VI. Discussion and Conclusions 
 
d(dinitro-C(O))TP was derived in part from the studies conducted by Stengel et al. 
using tC and tC(O). Whereas tC and tC(O) are derived from cytosine via an expansion of 
the carbon ring at the N4 and C5 positions (Stengel et al. 2009), dinitro-tC(O) expands on 
the structure of tC(O) through the addition of two nitro groups at the top of the tricyclic 
portion of the structure. Studies of dtCTP and dtC(O)TP found that these compounds 
hydrogen bond similarly to their parental structure cytosine, but extend their bulky 
tricyclic rings into the major groove of the DNA; despite this addition, KF is able to 
polymerize the compounds equally as efficiently as a dCTP analogue, and only 4-11 
times less efficiently as a dTTP analogue (Table 1). Thus, KF ambivalently incorporates 
dtCTP and dtC(O)TP opposite both A and G, which appears remarkable in light of the 
natural ability of KF to recognize mismatches (Stengel et al. 2009). 
KF incorporates d(dinitro-tC(O))TP efficiently opposite both A and G (Table 5.1), 
but with varying degrees. KF incorporates d(dinitro-tC(O))TP as efficiently as dTTP 
opposite A, and about twice as efficiently as dCTP opposite G (Table 5.1). A higher 
Vmax/Km indicates a higher affinity for the substrate; this would indicate that KF has the 
greatest affinity for d(dinitro-tC(O))TP as a T analogue. KF appears to have an equal 
affinity for dTTP upon incorporation opposite A as it does d(dinitro-tC(O))TP upon 
incorporation opposite G. Of all the substrates investigated, KF has the least affinity for 
incorporation of dCTP opposite G. Acting as a T and C analogue, this indicates that 
d(dinitro-tC(O))TP behaves as a pyrimidine analogue. 
Stengel et al. found that a dtC(O)TP-G base pair has a higher melting temperature 
than the canonical C-G base pair, leading to the conclusion that the novel compound 
lends a stabilizing effect to the duplex. This effect may be derived from π-π interactions 
between the aromatic tricycle and the heterocycles of the traditional bases. This is most 
likely true of d(dinitro-C(O))TP. 
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I propose that d(dinitro-tC(O))TP 
incorporates opposite A in the imino 
tautomer (Figure 6.1); in the same manner, 
d(dinitro-tC(O))TP most likely incorporates 
opposite G via the amino tautomer (Figure 
6.2). This is largely because the hydrogen 
bonding ability of d(dinitro-tC(O))TP 
should not differ from that of tC and tC(O); 
the nitro groups do not influence the 
compounds ability to pair with other bases. 
 The cytosine analogue dinitro-tC(O) 
and its sister compounds tC and tC(O) are a 
largely uncharted category of traditional 
nucleotide analogues; usually, nucleotide analogues are not quite as sizable as these 
compounds, but the size difference appears to have minimal effect on incorporation, 
particularly because hydrogen bonding patterns remain unaffected. A number of studies 
examine compounds in which the hydrogen bond donors and acceptors are substituted 
with differing chemical groups comparable in size to that which is being replaced, 
leading to the conclusion that 
hydrogen bonding is not the 
key component in correct 
polymerization- rather, 
concluded that size appears to 
be the deciding factor. (Kool 
2002; Henry and Romesberg 
2003). 
 My studies on d(dinitro-
tC(O))TP further supports the 
idea that selection for the 
correct nucleotide based on 
size is only true for analogues 
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Figure 6.1: Proposed hydrogen bonding of the imino 
tautomer of dinitro-tC(O) (right) with A (left). 
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Figure 6.2: Proposed hydrogen bonding of the amino 
tautomer of dinitro-tC(O) (right) with G (left). 
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closely related to the canonical bases. The size of d(dinitro-tC(O))TP is radically different 
from traditional nucleotides, and polymerization assays show that it can be incorporated 
efficiently but unselectively via KF, much like dtCTP and dtC(O)TP (Stengel et al. 2009). 
Studies of these compounds indicate that KF uses different mechanisms to select for the 
incoming nucleotide- and that both the size and hydrogen bonding patterns of the 
incoming nucleotide are equally important. 
 With d(dinitro-tC(O))TP, then, it would appear that its ability to hydrogen bond in 
the same pattern as its parent compound, cytosine, is sufficient to allow KF to identify it 
as correct. The function of the bulky cyclic addition that juts into the major groove is less 
clear. Because it is readily incorporated into the DNA strand, it does not appear to be 
detrimental enough to disqualify the compound as incorrect. d(dinitro-tC(O))TP is an 
exciting compound because it retains traditional hydrogen bonding properties, thereby 
maintaining the identified prerequisite for selection of the correct incoming nucleotide, 
but expands upon the traditional cytosine structure by expanding into the major groove. 
d(dinitro-tC(O))TP represents an expansion of the studies conducted by Stengel et al. by 
the addition of the nitro groups. tC and tC(O) express tenfold preference for C, whereas 
dinitro-tC(O) appears to exist in closer tautomeric equilibrium. Thus, the addition of nitro 
groups causes d(dinitro-tC(O))TP to be recognized more like T. Electron-withdrawing 
groups therefore has an undesirable effect, causing the strand to be less mutagenic, and 
future compounds to be explored should evaluate the effect of adding electron-donating 
groups to the structure. 
The development of nucleotide and nucleoside analogues over the past decade has 
resulted in the creation of a powerful tool against a variety of viruses and cancers. These 
compounds are structurally and mechanistically diverse, leading to a plethora of 
applications. As seen above, nucleotide and nucleoside analogues have progressed 
significantly and have a dramatic impact on cancer and viral therapeutics; the 
applications of these compounds clinically have led to the recognition of that which is 
beneficial and detrimental to the compounds therapeutically. Background research has 
worked to widen knowledge about the individual mechanisms of resistance to nucleotide 
and nucleoside analogues, such as cellular drug uptake, interaction with cellular targets, 
drug metabolism, and apoptosis. Researchers have taken this knowledge and applied it to 
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more compounds, expanding the library of agents available to patients (Jordheim et al. 
2013). Researchers are currently developing many additional agents that are presently in 
clinical trials. However, viruses continue to mutate and emerge, presenting a need for 
constant development of new compounds. Several viral infections, both life-threatening 
and not, do not have viable therapeutics, and could be addressed by new or repositioned 
nucleoside and nucleotide analogues. 
 There are still fundamental flaws in the nucleoside and nucleotide analogue 
therapeutic system. Viral genomes demonstrate strong variation, and viruses have 
heterogenous resistance mechanisms (Hurwitz and Schinazi 2013). Patients have diverse 
genetic variability. Nucleoside and nucleotide analogues can attack host nucleic acid, 
leading to extremely dangerous circumstances for the patient. Moreover, due to the 
novelty of the system, the cost of such therapeutics is not yet a viable, low-cost option for 
diseases in low-income countries, which is one of the places that needs it the most 
(Veltkamp et al. 2008). 
Nucleosides with ambivalent base pairing properties, like tC, tC(O) and dinitro-
tC(O), have the potential to have huge impacts on cancer therapeutics. This is because they 
can be introduced to the genome and incorporated extensively as mutagens, allowing the 
cell to recognize the sequence as error catastrophe. Currently, however, d(dinitro-
tC(O))TP is therapeutically unviable; it is unable to be phosphorylated in the cell, 
potentially due to inhibition of the kinases by the bulky cyclic structure. Further studies 
on d(dinitro-tC(O))TP could need to elucidate its mutagenic capabilities as the templating 
base, as the studies by Stengel et al. determined for tC and tC(O). If d(dinitro-tC(O))TP 
were to exhibit mutagenic capabilities in the templating strand, this would support 
multiple rounds of cell division, thereby making it a suitable candidate that would survive 
past the first few rounds of replication. Thus, it appears that the merit of d(dinitro-
tC(O))TP is founded in kinetic studies, not actual therapeutic application. Pursuit of a 
different compound, with electron-donating groups rather than electron-withdrawing 
groups, would be an interesting avenue for future research. It appears as though the 
addition of nitro groups shifts the tautomeric equilibrium from the amino preference of 
tC(O) to a greater preference for the imino tautomer. Perhaps the addition of electron-
donating groups would push the tC(O) compound significantly more towards the amino 
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tautomer. This would help to confirm the effects of adding electron-affective groups to 
nucleotide analogues. 
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